Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland

BioPharm International Editors

The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.

Celonic Group, a contract development and manufacturing organization (CDMO), announced on Feb. 25, 2021 that it has entered into a long-term lease agreement for a new production site and office space at the Novartis-operated Life Science Park Rheintal in Stein, Switzerland.

The 91,500-ft2 site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization, Celonic said in a company press release. The expansion will be completed in two phases and will add up to 20 GMP cleanroom suites and offices, along with laboratories for process development, method development, and quality control services.

“This expansion to the Life Science Park Rheintal demonstrates our commitment to address the growing demand for cell and gene therapy manufacturing. With its unique location and on-site services, this state-of-the-art facility will further boost Celonic’s expansion into the cell and gene space and enable us to offer large-scale ATMP (advanced therapy medicinal products) GMP manufacturing from early 2022,” said Konstantin Matentzoglu, CEO of Celonic, in the press release. “We are looking forward to establishing a world-class cell and gene therapy facility in this fast-developing life sciences hub operated by Novartis.”

Source: Celonic